GEN Exclusives

More »

GEN News Highlights

More »
Mar 17, 2011

Sanofi-Aventis Taps Epistem to Inform Biomarker Strategy for Cancer Drug Development

  • Sanofi-aventis will pay Epistem $4 million over three years in research support payments including reimbursement of certain costs to use its biomarker gene-expression profiling and immunohistochemistry technologies. Under the agreement Epistem will provide discovery through to clinical biomarker support for oncology programs being conducted by sanofi-aventis and its affiliates.

    The agreement aims at identifying biological responses to drugs in relevant tissues. Activities covered by the collaboration include preclinical, ex vivo, and clinical support.

    Epistem’s GenetRx™ biomarker technology is based on extracting mRNA from tissue biopsies, blood, and small amounts of surrogate tissue to measure drug-induced gene-expression change.Besides providing contract research services to drug development companies, the firm develops its own therapeutics, biomarkers, and diagnostics. It focuses on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast, and prostate.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?